We produced a monoclonal antibody (mAb) 
Three distinct types of methylated arginine, ADMA, N G ,N 0G -dimethyl-L-arginine (symmetric dimethylarginine or SDMA), and N G -monomethyl-L-arginine (MMA) occur in mammalian cells. They are generated by posttranslational modification due to protein arginine methyltransferase activities, 1) and are released in body fluids after in vivo protein breakdown. 2, 3) The methylated arginines are metabolized through common pathways catalyzed by aminotransferase or acetyltransferase. 4) ADMA and MMA are also degraded to citrulline and methylated amines by dimethylarginine dimethylaminohydrolase (DDAH). 5) Among methylated arginines, both of these amino acids are endogenous inhibitors of NOSs. [6] [7] [8] NOS activity in blood vessels mediates an important component of endothelium-dependent relaxation factor responses in blood vessels, 9) prevents vascular remodeling, 10, 11) and maintains stable blood pressure and renal vascular resistance. 12, 13) Consequently, DDAH has a pivotal role in maintaining the homeostatic integrity of the cardiovascular and renal systems. 14) Concentrations of circulating ADMA have been reported to increase in patients with established atherosclerosis, 15) peripheral vascular disease, 16) and coronary artery disease. 17) Thus ADMA is a significant endogenous inhibitor of NOSs and a risk factor for cardiovascular disease. It is important to monitor the concentrations of ADMA in human subjects and animals.
ADMA has been measured by high-performance liquid chromatography (HPLC) with fluorescence detection, [18] [19] [20] and mass spectrometry (MS) such as LC-MS and gas chromatography (GC)-MS. 21, 22) However, these methods have disadvantages, such as difficulty in getting reproducible results and the necessity of using expensive instruments. Alternatively, ELISA would be useful for the measurement of ADMA in samples and is suitable for the handling of large numbers of samples.
In the present study, we prepared and characterized three mAbs raised against ADMA conjugated to BSA with a heterobifunctional cross-linker, N-succinimidyl 3-maleimidobenzoate (SMB), and applied an mAb to construct an ELISA system for the measurement of concentrations of ADMA in biological samples. This study was approved by the Institutional Review Board of Okayama Prefectural University, and was conducted in compliance with the spirit of the Helsinki Declaration of 1964 (revised in 2008).
First, we synthesized ADMA conjugated with BSA via SMB by methods of Kitagawa et al. 23) The conjugate (ADMA-SMB-BSA), purified by Sephacryl S-300 gel filtration chromatography, was used as source of the immunogen or solid-phase antigen. In addition, ADMA, was conjugated to mouse serum albumin (MSA) using disuccimidyl suberate (DSS) as cross-linker following the manufacturer's instructions to serve as antigen for screening hybridomas and coating the bottoms of microtiter plate wells. This conjugate was named ADMA-DSS-MSA. Immunization of 6-week old BALB/c mice, cloning of hybridoma cells, and the production of mAbs against the antigen were done in the manner described in a previous paper. 24) Finally, three clones of hybridomas, 2G3, 3C12, and 3E11, were established. These mAbs were produced in ascitic fluids of BALB/c mice by priming with pristane and intraperitoneal injection with established hybridomas, and purified by protein A affinity chromatography with an Affi-gel Protein A MAPS II Kit (Bio-Rad, Hercules, CA, USA).
The sensitivities and specificities of the 2G3, 3C12, and 3E11 mAbs were analyzed by means of competitive inhibition ELISA using the ADMA-SMB-BSA conjuy To whom correspondence should be addressed. Tel/Fax: +81-866-94-2158; E-mail: kimoto@fhw.oka-pu.ac.jp Abbreviations: ADMA, asymmetric dimethylarginine; BSA, bovine serum albumin; DDAH, dimethylarginine dimethylaminohydrolase; DSS, disuccinimidyl suberate; ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography-mass spectrometry; mAb, monoclonal antibody; MMA, N G -monomethyl-L-arginine; MSA, mouse serum albumin; NOS, nitric oxide synthase; SDMA, symmetric dimethylarginine; SMB, N-succinimidyl 3-maleimidobenzoate gate coated on the wells of plates (Fig. 1) . This was based on the principle of competition between ADMA or related analogs and a fixed amount of the bound antigen for a limited number of binding sites on the mAb. All three mAbs showed about 1 Â 10 4 to 1 Â 10 6 -fold higher sensitivity to SMB-ADMA conjugate than ADMA. This suggests that mAbs recognize rather strongly the acylamide linkage formed between ADMA and SMB in the solid phase antigen. To measure ADMA in samples, it is necessary to acylate ADMA with SMB. 2G3 was found to react not only with SMB-ADMA, but also with SMB-arginine and -SDMA (Fig. 1A) . This indicates that 2G3 is not promising as an mAb suitable for the measurement of ADMA due to a lack of specificity for ADMA. The other mAbs, 3C12 and 3E11, exhibited similar immunoreactivity to the various competitors tested in this study, and their cross-reactivities to SMB-L-arginine were less than 0.01% of that to SMB-ADMA, which appears to be essentially of no significance when assaying ADMA in human plasma or urine. However, 3C12 was found to be more sensitive to ADMA than 3E11. These observations indicate that 3C12 is the most suitable for the development of ELISA to measure ADMA. Hence, 3C12 was used in subsequent experiments. An optimal assay condition of the competitive ELISA for ADMA was established with mAb 3C12 (Fig. 2) . The present ELISA system is based on competition with a competitor, SMB-ADMA, on the wells of a microtiter plate coated with ADMA-SMB-BSA conjugate. The acylated derivative of ADMA in pre-treated samples and ADMA-SMB-BSA on the wells compete on the limited number of binding sites of the mAb. The calibration curve obtained with ADMA directly acylated with SMB in a test tube was almost identical with that of authentic SMB-ADMA, indicating that pre-treatment with SMB resulted in quantitative conversion of ADMA to SMB-ADMA. Compared with the methods available for the measurement of ADMA, the present ELISA has advantages, including ease of use and a non-isotopic assay. The combination of the acylation step and the competitive inhibition design of the ELISA resulted in a specific, highly sensitive method. Schulze et al. Immunoreactivity was examined by competitive inhibition ELISA as follows: The wells of microtiter plates were coated with 100 mL of ADMA-SMB-BSA conjugate (0.1 mg/mL) in PBS at 4 C overnight, and then the antigen solution was removed from the wells, and the wells incubated with 3% skimmed milk in PBS containing 0.05% Tween 20 (PBST) at 37 C. After 1 h, the wells were reacted with 100 mL of the reaction mixture containing a mAb (5 ng) and a competitor ranging from 10 nM to 10 mM at 37 C for 1 h. After washing with PBST 3 times, the immunocomplexes on the wells were incubated with peroxidase-conjugated goat anti-mouse IgG (5,000-fold diluted) at 37 C. After 1-h of incubation, the wells were washed 3 times with PBST and the immuncomplexes were visualized by peroxidase reaction with a cocktail consisting of o-phenylenediamine and H 2 O 2 in 0.1 M citrate buffer (pH 5.0). The absorbance of the reaction mixtures in the wells at 490 nm was measured with a microplate reader. Authentic SMB-ADMA conjugate, used as a competitor, was synthesized as described in the text. An aliquot of the aqueous solution containing SMB-ADMA was hydrolyzed with 5 M HCL at 100 C for 1 h and subjected to amino acid analysis for ADMA measurement. The untreated solution was found not to contain any ADMA, and the expected amount of ADMA was obtained in the hydrolysate. Other SMB conjugates were prepared in the same manner as in the case of SMB-ADMA. , ADMA; , SMB-ADMA; , SDMA; , SMB-SDMA; , L-arginine; , SMB-L-arginine. This experiment was done in order to confirm the quantitative conversion of ADMA to SMB-ADMA in given reaction tubes. The ADMA in each tube was directly acylated with SMB as follows: 60 mL of authentic ADMA diluted to various extents with 0.1 M phosphate buffer (pH 7.2) was mixed with 20 mL of SMB (30 mg/mL) in DMSO, and incubated at room temperature for 30 min with stirring. The reaction mixture was then centrifuged at 4 C, at 10;000 Â g for 1 h. An aliquot (15 mL) of the prepared supernatant and mAb 3C12 (25 ng/500 mL) were mixed, and then 100 mL of the reaction mixture was subjected to competitive ELISA ( ). On the other hand, known amounts of authentic SMB-ADMA were used for the assay ( ). The numbers on the abscissa indicate the final concentration of competitor in a well.
developed an ELISA kit for ADMA based on the same concept as our ELISA system, and reported that their ELISA method quantified 50 nM ADMA as the lowest concentration. The fact that our method can determine 5 nM ADMA as the lowest concentration suggests that our ELISA method is superior to the conventional method with regard to sensitivity.
Using this competitive ELISA, we measured the concentrations of ADMA in plasma and urine samples from healthy human subjects (Table 1 ). The ADMA concentrations in plasma of healthy individuals reported by different groups of investigators vary from approximately 0.12 to 2.4 mM. [18] [19] [20] [21] [22] The implications of these findings are that not all current assays can accurately determine ADMA in plasma with satisfying results, and that there is the variation in ADMA levels between laboratories using different analytical methods. As shown in Table 1 , the mean value of the ADMA concentration in human plasma as measured by our competitive ELISA was 0:78 AE 0:09 mM, which lies within a much narrower concentration range, 0.59-0.82 mM, the values determined by some investigators using ELISA. 26, 27) Furthermore, the concentration of ADMA in human urine was found to be 51:3 AE 11:1 mmol/g creatinine (n ¼ 4). In contrast to plasma, few data as to the concentrations of ADMA in urine of healthy subjects have been reported, [28] [29] [30] obtained by GC-MS or LC-MS/MS. Hence, it is not possible to make a useful comparison between our method and other different analytical approaches. However, the calculated mean value of the concentration of ADMA in the urine of healthy adults was found to be similar to those published previously. [28] [29] [30] In general, the precision of a quantitative assay system can be assessed by intra-assay and inter-assay coefficients of variation. As shown in Fig. 2 , the intra-assay coefficients of variation estimated by repeated measurement at three different concentrations of authentic ADMA were low (4.2% on average). The inter-assay coefficients of variation for the measurement of ADMA in human urine also exhibited low levels (4.0% on average, Table 1 ). In comparison to these data, the coefficients of variation on the inter-assay with human plasma were higher ( Table 1 ), suggesting that the accuracy of competitive ELISA for the measurement of plasma ADMA is affected by the components in the blood. 25) In conclusion, the present findings indicate that mAb 3C12 is the most suitable for the development of a competitive ELISA for the measurement of ADMA in biological fluids, and that the present ELISA method, characterized by simplicity, sensitivity and specificity, can measure the concentrations of ADMA in large numbers of samples efficiently. Table 1 . ADMA Concentrations in Human Plasma and Urine Plasma (A, B, C, D) and spot urine (E, F, G, H) samples were collected from eight human volunteers who were all apparently healthy, and the amounts of ADMA in the samples were determined by competitive ELISA as described in the footnote to Fig. 2 . When a plasma sample was mixed with 50 nM authentic ADMA externally added, the recovery of the added ADMA was calculated from the standard curve for ELISA. 
